| Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells W Yang, J Soares, P Greninger, EJ Edelman, H Lightfoot, S Forbes, ... Nucleic acids research 41 (D1), D955-D961, 2012 | 3436 | 2012 |
| Systematic identification of genomic markers of drug sensitivity in cancer cells MJ Garnett, EJ Edelman, SJ Heidorn, CD Greenman, A Dastur, KW Lau, ... Nature 483 (7391), 570-575, 2012 | 2662 | 2012 |
| A landscape of pharmacogenomic interactions in cancer F Iorio, TA Knijnenburg, DJ Vis, GR Bignell, MP Menden, M Schubert, ... Cell 166 (3), 740-754, 2016 | 1934 | 2016 |
| A gene expression signature associated with “K-Ras addiction” reveals regulators of EMT and tumor cell survival A Singh, P Greninger, D Rhodes, L Koopman, S Violette, N Bardeesy, ... Cancer cell 15 (6), 489-500, 2009 | 912 | 2009 |
| Patient-derived models of acquired resistance can identify effective drug combinations for cancer AS Crystal, AT Shaw, LV Sequist, L Friboulet, MJ Niederst, EL Lockerman, ... Science 346 (6216), 1480-1486, 2014 | 823 | 2014 |
| Targeting MYCN in neuroblastoma by BET bromodomain inhibition A Puissant, SM Frumm, G Alexe, CF Bassil, J Qi, YH Chanthery, ... Cancer discovery 3 (3), 308-323, 2013 | 736 | 2013 |
| Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors U McDermott, AJ Iafrate, NS Gray, T Shioda, M Classon, S Maheswaran, ... Cancer research 68 (9), 3389-3395, 2008 | 514 | 2008 |
| Synthetic lethal interaction of combined BCL-XL and MEK inhibition promotes tumor regressions in KRAS mutant cancer models RB Corcoran, KA Cheng, AN Hata, AC Faber, H Ebi, EM Coffee, ... Cancer cell 23 (1), 121-128, 2013 | 423 | 2013 |
| AMG 176, a selective MCL1 inhibitor, is effective in hematologic cancer models alone and in combination with established therapies S Caenepeel, SP Brown, B Belmontes, G Moody, KS Keegan, D Chui, ... Cancer discovery 8 (12), 1582-1597, 2018 | 415 | 2018 |
| Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling U McDermott, SV Sharma, L Dowell, P Greninger, C Montagut, J Lamb, ... Proceedings of the National Academy of Sciences 104 (50), 19936-19941, 2007 | 406 | 2007 |
| TAK1 inhibition promotes apoptosis in KRAS-dependent colon cancers A Singh, MF Sweeney, M Yu, A Burger, P Greninger, C Benes, DA Haber, ... Cell 148 (4), 639-650, 2012 | 328 | 2012 |
| KRAS G12C NSCLC models are sensitive to direct targeting of KRAS in combination with PI3K inhibition S Misale, JP Fatherree, E Cortez, C Li, S Bilton, D Timonina, DT Myers, ... Clinical Cancer Research 25 (2), 796-807, 2019 | 239 | 2019 |
| Targeting aberrant glutathione metabolism to eradicate human acute myelogenous leukemia cells S Pei, M Minhajuddin, KP Callahan, M Balys, JM Ashton, SJ Neering, ... Journal of Biological Chemistry 288 (47), 33542-33558, 2013 | 232 | 2013 |
| Isocitrate dehydrogenase mutations confer dasatinib hypersensitivity and SRC dependence in intrahepatic cholangiocarcinoma SK Saha, JD Gordan, BP Kleinstiver, P Vu, MS Najem, JC Yeo, L Shi, ... Cancer discovery 6 (7), 727-739, 2016 | 165 | 2016 |
| Detection of dysregulated protein-association networks by high-throughput proteomics predicts cancer vulnerabilities JD Lapek Jr, P Greninger, R Morris, A Amzallag, I Pruteanu-Malinici, ... Nature biotechnology 35 (10), 983-989, 2017 | 154 | 2017 |
| Venetoclax is effective in small-cell lung cancers with high BCL-2 expression TL Lochmann, KV Floros, M Naseri, KM Powell, W Cook, RJ March, ... Clinical cancer research 24 (2), 360-369, 2018 | 132 | 2018 |
| Differential effector engagement by oncogenic KRAS TL Yuan, A Amzallag, R Bagni, M Yi, S Afghani, W Burgan, N Fer, ... Cell reports 22 (7), 1889-1902, 2018 | 129 | 2018 |
| Ligand-dependent platelet-derived growth factor receptor (PDGFR)-α activation sensitizes rare lung cancer and sarcoma cells to PDGFR kinase inhibitors U McDermott, RY Ames, AJ Iafrate, S Maheswaran, H Stubbs, ... Cancer Research 69 (9), 3937-3946, 2009 | 115 | 2009 |
| Targeting MYCN in neuroblastoma by BET bromodomain inhibition. Cancer Discov. 2013; 3: 308–323. doi: 10.1158/2159-8290 A Puissant, SM Frumm, G Alexe, CF Bassil, J Qi, YH Chanthery, ... CD-12-0418.[Europe PMC free article][Abstract][CrossRef][Academic Search], 0 | 102 | |
| A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers SM Rothenberg, G Mohapatra, MN Rivera, D Winokur, P Greninger, ... Cancer research 70 (6), 2158-2164, 2010 | 95 | 2010 |
